logo
logo

Nautilus Biotechnology Raises $76 Million in Series B Funding to Be the First to Quantify the Human Proteome

May 21, 2020about 5 years ago

Amount Raised

$76 Million

Round Type

series b

San Carlos

Description

Nautilus Biotechnology, a company pioneering a high-throughput, low-cost platform for analyzing and quantifying the human proteome, today announced it has raised $76 million in an oversubscribed Series B offering that closed on Monday, May 18, 2020. Nautilus’ total funding now exceeds $100 million. The Nautilus platform will deliver single-molecule sensitivity more quickly, more completely, and less expensively than is possible with existing technologies. This deeper, richer understanding of proteins will enable a dramatic acceleration of basic science research, significantly improve the success rate of therapeutic development, and speed the adoption of personalized and predictive medicine.

Company Information

Company

Nautilus Biotechnology

Location

San Carlos, California, United States

About

Based in San Carlos, CA and Seattle, WA, Nautilus is a biotechnology company whose proteomics platform will deliver superior sensitivity far more quickly, more completely, and less expensively than is currently possible. By breaking through the limitations of existing technologies, and effectively democratizing proteomics, Nautilus will enable a dramatic acceleration of basic science research, significantly improve the success rate of therapeutic development, and usher in a new era of personalized and predictive medicine. Find Nautilus online: www.nautilus.bio

Related People

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech